Leveraging molecular dynamics simulations to study psychedelics and their receptors in future drug development.

Psychedelics hold therapeutic promise for central nervous system disorders but are limited by hallucinogenic side effects. Molecular dynamics simulations provide atomic-level insights into receptor interactions, helping to overcome these challenges and guide the development of safer, more effective therapies. This perspective reviews how MD simulations reveal mechanisms such as biased signaling, receptor multimerization, and lipid modulation, and discusses their role in validating cryo-EM binding sites. Challenges in force fields, structural data, and system complexity must be addressed to advance rational drug design. MD simulations are transforming psychedelic drug discovery from serendipity to precision design, with the goal of a predictive 'digital pharmacology' platform.

Study at a glance

Abstract

Psychedelics show great promise for treating Central Nervous System (CNS) disorders but are limited by side effects like hallucinations. Molecular dynamics (MD) simulations offer atomic-level insights into receptor interactions, helping to overcome these challenges and guide the development of safer, more effective psychedelic-based therapies. This perspective reviews how MD simulations provide atomic-level insights into key psychedelic-receptor mechanisms: biased signaling, receptor multimerization, and lipid modulation. We also discuss MD's role in validating cryo-EM binding sites, alongside challenges in force fields, structural data, and system complexity that must be overcome to advance rational CNS drug design. MD simulations are transforming psychedelic drug discovery from serendipity to precision design. While immediate impact lies in accelerating lead optimization through in silico screening of biased signaling and multimer-selective compounds, broader adoption requires closing the translational gap between simulation predictions and in vivo outcomes. Key advancements will come from AI-refined force fields, integrative structural modeling of receptor complexes, and coupling MD with kinetic pharmacology. The ultimate goal is a predictive 'digital pharmacology' platform. Within five years, cloud-based MD screening is expected to become standard, delivering safer, mechanism-based clinical candidates and paving the way for personalized neurotherapeutics.